Personalized nutrition strategy is key in CF, patient interviews show
Nutritionists help patients meet goals, while high food costs can be barrier Lindsey Shapiro, PhD People living with cystic fibrosis ...
CF Foundation invests over $7M to support phage therapy development
Virus-based treatments may help CF patients with Pseudomonas infections by Marisa Wexler, MS | September 15, 2025 The Cystic Fibrosis...
How Cystic Fibrosis Went From Fatal to Treatable
Jennifer Abbasi 1 When physician-scientist Michael J. Welsh, MD, was starting out as a medical student in the 1970s, cystic fibrosis ...
Nanoparticles in gene-editing therapy may correct CF defects
Optimizing nanoparticles, mucus-clearing treatment made therapy more efficient by Steve Bryson, PhD | September 9, 2025 Researchers have...
A huge turning point: CF medicine’s Trikafta/Kaftrio added to WHO Essential Medicines List
Today marks a historic breakthrough in the fight for global access to lifesaving cystic fibrosis (CF) treatment. The World Health...
Lipidome profile of Cystic Fibrosis Related Diabetes, Type 1 and Type 2 Diabetes Mellitus: potential links to inflammation and glucose and lipid metabolism.
Alessandra Mingione, Cristian Loretelli, Michele Dei Cas, Francesca Pivari, Matteo Barcella, Ivan Merelli, Aida Zulueta, Rita Paroni,...
CFTR profiles and phenotypic associations in Pakistani children and adults with suspected cystic fibrosis
Javeria Aijaz, Zaira Rehman, Saima Ali, Saba Shahid, Ali Akbar, Muhammad Fareeduddin* For detailed information, please click and download...
Trial tests new approach with CFTR modulators for cystic fibrosis
First participants dosed in Phase 1 study of drug combination The first participants have been dosed in a clinical trial that’s testing...
Change in pulmonary pathogens three years after elexacaftor/tezacaftor/ivacaftor: an observational study in the Danish cystic fibrosis cohort
Maria Pals Bendixen 1 ∗ , Majbritt Jeppesen 2 ∗ , Oihane Irazoki 1 3 , Camilla Bjørn Jensen 4 , Mikala Wang 5 , Janne Petersen 4 6 ,...
Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy
The funding will support preclinical research focused on the nonsense mutation G542X BETHESDA, Md. (July 16, 2025) – Today, the Cystic...
